Beijing Tiantan Biological Products Hits Day Low Amid Price Pressure at CNY 14.71

Beijing Tiantan Biological Products Corp. experienced a notable decline in its stock performance today, with a decrease of 4.64% as of March 23, 2026. The stock reached an intraday low of CNY 14.71, reflecting ongoing challenges within the company. Over the past week, the stock has fallen by 7.85%, and its performance over the last month shows a decline of 9.26%. In a broader context, the stock has underperformed significantly compared to the China Shanghai Composite, which has seen a decline of 3.63% today. Over the past year, Beijing Tiantan's stock has dropped by 25.83%, contrasting sharply with the Composite's gain of 13.33%. Financial metrics indicate a concerning trend, with net sales decreasing by 24.69% and operating cash flow at its lowest point of CNY -324.97 million. The company's return on equity stands at 15.75%, while its debt-equity ratio is reported at -0.15. These figures highlight the challenges faced by Beijing Tiantan in maintaining its market position within the pharmaceuticals and biotechnology sector.